Natalie Halladin Selected Research

IDegLira

1/2021	The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
1/2020	A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
2/2019	EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.
1/2019	Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
1/2019	Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
1/2018	Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
1/2017	Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Natalie Halladin Research Topics

Disease

7	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2017
4	Weight Gain 01/2021 - 01/2018
3	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 01/2018
2	Weight Loss (Weight Reduction) 01/2021 - 01/2018
2	Body Weight (Weight, Body) 01/2019 - 01/2018
1	Body Weight Changes 01/2020
1	Nausea 01/2019
1	ST Elevation Myocardial Infarction 12/2017
1	Myocardial Ischemia (Ischemic Heart Diseases) 12/2017
1	Reperfusion Injury 12/2017

Drug/Important Bio-Agent (IBA)

7	IDegLiraIBA 01/2021 - 01/2017
6	Liraglutide FDA Link 01/2021 - 01/2017
6	insulin degludecIBA 01/2021 - 01/2017
6	Insulin (Novolin)FDA Link 01/2021 - 01/2017
5	Insulin Glargine (Lantus)FDA Link 01/2020 - 01/2018
4	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2017
4	Hypoglycemic Agents (Hypoglycemics)IBA 01/2020 - 01/2017
3	Blood Glucose (Blood Sugar)IBA 01/2021 - 01/2018
1	Hemoglobins (Hemoglobin)IBA 02/2019
1	Glucagon-Like Peptide-1 ReceptorIBA 02/2019
1	SodiumIBA 01/2019
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2019
1	Lipase (Acid Lipase)FDA Link 01/2019
1	Metformin (Glucophage)FDA LinkGeneric 01/2018
1	Insulin Aspart (NovoLog)FDA Link 01/2018
1	MelatoninIBA 12/2017

Therapy/Procedure

4	Therapeutics 01/2021 - 01/2018
1	Injections 01/2019
1	Percutaneous Coronary Intervention 12/2017